Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.60 |
| ▸ | BLM | P54132 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | MVD | P53602 | 3/20 | 0.35 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Triphosphate SCHEMBL15555988 | 0.93 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL18714 | 0.93 | FDPS (0.69) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL5324872 | 0.90 | FDPS (0.56) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL36119 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL22717549 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL25284822 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL11149492 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL21246913 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| SCHEMBL897837 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 | |
| Triphosphate SCHEMBL3385312 | 0.89 | FDPS (0.64) | FDPSBLMTDP1BTN3A1CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999098-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | SOLULINK BIOSCIENCES, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-08-02 | — | — | US | disclosed |
| US-7173125-B2 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2007-02-06 | — | — | US | disclosed |
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | AUDAX PRIVATE DEBT LLC, AS AGENT | 2004-10-28 | — | — | US | disclosed |
| US-6686461-B1 | HYDRAZINO, OXYAMINO AND CARBONYL-BASED MONOMERS AND METHODS FOR LABELLING OF OLIGONUCLEOTIDES WITHOUT THE NEED FOR POST-SYNTHETIC MODIFICATION | SOLULINK BIOSCIENCE, INC. | 2004-02-03 | — | — | US | disclosed |
| EP-1305327-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | Schwartz, David A. (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002010432-A2 | TRIPHOSPHATE OLIGONUCLEOTIDE MODIFICATION REAGENTS AND USES THEREOF | SCHWARTZ DAVID A (US) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214199-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | FDPS 1899/4885BLM 1426/4885TDP1 374/4885 |
| US-20070179288-A1 | Triphosphate oligonucleotide modification reagents and uses thereof | RNGTT, DUT, NUDT1 | FDPS 1883/4885BLM 1350/4885TDP1 392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.